



Blincyto™ (blinatumomab) – Expanded orphan indication

- On March 29, 2018, the [FDA announced](#) the approval of Amgen's [Blincyto \(blinatumomab\)](#) for the treatment of B-cell precursor acute lymphoblastic leukemia (ALL) in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1% in adults and children.
 - Previously, Blincyto was approved for the treatment of relapsed or refractory B-cell precursor ALL in adults and children.
- B-cell precursor ALL is a rapidly progressing type of cancer in which the bone marrow makes too many B-cell lymphocytes, an immature type of white blood cell. MRD is the presence of malignant cells detectable with more sensitive testing methods despite complete remission by standard assessment. MRD represents a significant risk factor for relapse.
 - The National Cancer Institute estimates that approximately 5,960 people in the U.S. will be diagnosed with ALL this year and approximately 1,470 will die from the disease.
- Blincyto is the first FDA-approved treatment for patients with MRD-positive ALL.
- The efficacy of Blincyto in MRD-positive ALL was demonstrated in the open-label [BLAST study](#) treating 86 adults in first or second complete remission. Efficacy was based on achievement of undetectable MRD within one cycle of Blincyto treatment and hematological relapse-free survival (RFS).
 - Undetectable MRD was achieved by 81.4% of patients (95% CI: 71.6, 89.0).
 - The median hematological RFS was 22.3 months.
- Blincyto carries boxed warnings for cytokine release syndrome and neurological toxicities.
- The recommended dose of Blincyto for patients ≥ 45 kg is 28 mcg/day from days 1 - 28 of the cycle, followed by a 14-day treatment-free interval. Up to 3 additional consolidation cycles may be provided.
 - For patients < 45 kg, the dose is calculated using the patient's body surface area. Refer to the Blincyto drug label for dosing recommendations



optumrx.com

OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at optum.com.

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2018 Optum, Inc. All rights reserved.